graft vs host reaction

Summary

Summary: An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.

Top Publications

  1. ncbi Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR
    Markus Y Mapara
    Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Biol Blood Marrow Transplant 12:623-34. 2006
  2. ncbi Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation
    A Leo
    Institute for Immunology and the Department of Internal Medicine, University Clinics of Heidelberg, Heidelberg, Germany
    Transfusion 40:632-6. 2000
  3. ncbi Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation
    Steven Z Pavletic
    University of Nebraska Medical Center, Omaha, USA
    Blood 106:3308-13. 2005
  4. ncbi Partial HLA matching and RH incompatibility resulting in graft versus host reaction and Evans syndrome after liver transplantation
    Celia Grosskreutz
    Bone Marrow Transplantation Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai Medical Center, New York, New York, USA
    Am J Hematol 83:599-601. 2008
  5. ncbi In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens
    Anne M Dickinson
    University Department of Haematology, Royal Victoria Infirmary, University of Newcastle, Newcastle upon Tyne, UK
    Nat Med 8:410-4. 2002
  6. ncbi Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-host reaction in a rat skin explant model
    Peter Novota
    Department of Cellular and Molecular Immunology, University of Gottingen, Gottingen, Germany
    Transplantation 85:1809-16. 2008
  7. ncbi Haploidentical donor T cells fail to facilitate engraftment but lessen the immune response of host T cells in murine fetal transplantation
    Jeng-Chang Chen
    Fetal Treatment Center, Department of Surgery, University of California, San Francisco, CA 94143-0793, USA
    Br J Haematol 126:377-84. 2004
  8. ncbi Correlation of donor-derived keratinocytes and severity of graft-versus-host disease (GVHD) in epidermis
    Daisuke Niino
    Department of Molecular Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
    Pathol Res Pract 200:775-81. 2005
  9. ncbi Levels of anti-A/B antibodies after ABO-incompatible hematopoietic stem cell transplantation
    G Stussi
    Laboratory for Transplantation Immunology, , Switzerland
    Transplant Proc 37:1385-7. 2005
  10. ncbi Post-transplantation dynamics of the immune response to chronic myelogenous leukemia
    Rob DeConde
    Stanford Medical Informatics, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    J Theor Biol 236:39-59. 2005

Detail Information

Publications116 found, 100 shown here

  1. ncbi Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR
    Markus Y Mapara
    Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Biol Blood Marrow Transplant 12:623-34. 2006
    ....
  2. ncbi Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jk(a) after allogeneic PBPC transplantation
    A Leo
    Institute for Immunology and the Department of Internal Medicine, University Clinics of Heidelberg, Heidelberg, Germany
    Transfusion 40:632-6. 2000
    ..After allogeneic peripheral blood progenitor cell (PBPC) transplantation, a patient developed a severe hemolytic transfusion reaction due to passenger lymphocyte syndrome...
  3. ncbi Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation
    Steven Z Pavletic
    University of Nebraska Medical Center, Omaha, USA
    Blood 106:3308-13. 2005
    ..In spite of a significant reduction of acute GVHD, TCD did not reduce the incidence of cGVHD or improve survival in patients who developed cGVHD...
  4. ncbi Partial HLA matching and RH incompatibility resulting in graft versus host reaction and Evans syndrome after liver transplantation
    Celia Grosskreutz
    Bone Marrow Transplantation Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai Medical Center, New York, New York, USA
    Am J Hematol 83:599-601. 2008
    ..HLA typing was critical in confirming this rare diagnosis and elucidating its cause. Recipients of solid organs from donors that are partially matched in the direction of rejection may need to be closely monitored for GVHD...
  5. ncbi In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens
    Anne M Dickinson
    University Department of Haematology, Royal Victoria Infirmary, University of Newcastle, Newcastle upon Tyne, UK
    Nat Med 8:410-4. 2002
    ..These results provide the first in situ dissection of GvH effects by mHag-specific CTLs and show that ubiquitously expressed mHags are the prime targets of GvH disease...
  6. ncbi Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-host reaction in a rat skin explant model
    Peter Novota
    Department of Cellular and Molecular Immunology, University of Gottingen, Gottingen, Germany
    Transplantation 85:1809-16. 2008
    ..New molecular markers of GVHR might help to further increase the predictive value of the assay...
  7. ncbi Haploidentical donor T cells fail to facilitate engraftment but lessen the immune response of host T cells in murine fetal transplantation
    Jeng-Chang Chen
    Fetal Treatment Center, Department of Surgery, University of California, San Francisco, CA 94143-0793, USA
    Br J Haematol 126:377-84. 2004
    ..The persistence of donor cells in the peritoneal cavity also correlated with tolerance induction...
  8. ncbi Correlation of donor-derived keratinocytes and severity of graft-versus-host disease (GVHD) in epidermis
    Daisuke Niino
    Department of Molecular Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
    Pathol Res Pract 200:775-81. 2005
    ..We hypothesize that donor-derived stem cells may play a role in the regeneration of damaged keratinocytes in GVHD...
  9. ncbi Levels of anti-A/B antibodies after ABO-incompatible hematopoietic stem cell transplantation
    G Stussi
    Laboratory for Transplantation Immunology, , Switzerland
    Transplant Proc 37:1385-7. 2005
    ..Thus, there is no evidence for stimulation of donor B lymphocytes to produce antirecipient antibodies suggesting a potential B cell tolerance...
  10. ncbi Post-transplantation dynamics of the immune response to chronic myelogenous leukemia
    Rob DeConde
    Stanford Medical Informatics, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    J Theor Biol 236:39-59. 2005
    ..These observations lead to the hypothesis that anti-host T cells benefit from stimulation by general host blood cells, which induce them to proliferate to sufficient levels to eliminate cancer...
  11. ncbi Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease
    Søren L Petersen
    Department of Hematology, Rigshospitalet, Copenhagen, Denmark
    Biol Blood Marrow Transplant 10:337-46. 2004
    ..A donor CD8(+) T-cell count above the median on day +14 increased the risk of subsequent development of aGVHD grades II to IV (P =.003)...
  12. ncbi Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma
    Thomas Luft
    Department of Hematology and Rheumatology, University of Heidelberg, Poliklinik and Medizinische Klinik V, Heidelberg, Germany
    Br J Haematol 123:646-53. 2003
    ..Secondly, the graft-versus-myeloma effect that induced CR did not correlate with FDC but was associated with grade III-IV GvHD in our group of heavily pretreated patients...
  13. ncbi Positive and negative selection of T cell repertoires during differentiation in allogeneic bone marrow chimeras
    Kazunori Onoe
    Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
    Transpl Immunol 12:79-88. 2003
    ..In this communication, the contribution of BM chimera systems to the investigation of the world of T-ology is discussed...
  14. ncbi Syngeneic graft-versus-host disease: a report of two cases and literature review
    T Latif
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland, OH 44195, USA
    Bone Marrow Transplant 32:535-9. 2003
    ..The current report reviews these cases and presents two additional cases of severe SGVHD that have occurred at our institution...
  15. ncbi Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection
    Marlies E J Reinders
    Department of Medicine, and Department of Pediatrics Children s Hospital, Boston, Massachusetts 02115, USA
    Transplantation 76:224-30. 2003
    ..However, little is known of the expression or function of VEGF in acute and chronic allograft rejection...
  16. ncbi [Experimental study of optimized H-2 haploidentical hematopoietic engraftment for the treatment of murine acute leukemia model]
    Fan-yi Meng
    Department of Hematology, Nanfang Hospital, the First Military Medical University of PLA, Guangzhou 510515, China
    Zhonghua Xue Ye Xue Za Zhi 24:197-9. 2003
    ..Those mice transfused with CD(3)(+) T lymphocyte in the graft higher than 10(8) cells died from the GVHD was significantly higher. The inclusive dosage of 5 x 10(7) CD(3)(+) T lymphocyte was enough to separate the GVHD from GVL...
  17. ncbi [Allogeneic adoptive immunotherapy]
    P Tiberghien
    Inserm EPI 0119 Upres EA 2284, Etablissement Français du Sang Bourgogne Franche Comté, Universite de Franche Comte, 1, Boulevard Alexandre Fleming, BP 1937, 25020 cedex, Besancon, France
    Transfus Clin Biol 10:170-4. 2003
    ..Such a transplant modality is now perceived has a very efficient form of adoptive allogeneic immunotherapy unfortunately associated with significant toxicity...
  18. ncbi Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction
    Masako Murai
    Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo ku, Japan
    Nat Immunol 4:154-60. 2003
    ..Mice deficient for PPs failed to develop a-GVHD in two models of disease induction. Thus, blockade of CTL generation in PPs might offer new strategies for circumventing a-GVHD...
  19. ncbi Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Blood 101:1422-9. 2003
    ..Whether these results support a separation of deleterious from beneficial graft-host interactions at the level of antigen presentation, rather than solely at the level of T cells, will require further evaluation...
  20. ncbi Differential sensitivity of T lymphocytes and hematopoietic precursor cells to photochemotherapy with 8-methoxypsoralen and ultraviolet A light
    Mohamed Mabed
    Hematology and Medical Oncology Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt
    Ann Hematol 85:17-24. 2006
    ..Taken together, these data show that ex vivo 8-MOP plus UV-A treatment of the marrow graft cannot be used to prevent post-bone marrow transplantation alloreactivity...
  21. ncbi Case of a patient with progressive adult T-cell leukemia/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor
    Hiroshi Fujiwara
    Division of Hematology Immunology, Internal Medicine, Kagoshima University Hospital, Japan
    Int J Hematol 82:357-61. 2005
    ..In addition, basiliximab combined with MMF may be effective for the treatment of steroid-refractory skin GVHD without deteriorating the graft-versus-ATL effect...
  22. ncbi Chimerism studies as an approach for the induction of tolerance to extremity allografts
    Keiichi Muramatsu
    Department of Orthopedic Surgery, Yamaguchi University School of Medicine, Yamaguchi, Japan
    J Plast Reconstr Aesthet Surg 61:1009-15. 2008
    ..In this review, recent experimental chimerism studies are presented for tolerance induction and we review the prospect of clinical applicability in extremity allograft...
  23. ncbi The thymus in GVHD pathophysiology
    Werner Krenger
    Laboratory of Pediatric Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland
    Best Pract Res Clin Haematol 21:119-28. 2008
    ..The present review focuses on recent insight into how GVHD affects thymic function and how this knowledge aides the design of new strategies to improve immune reconstitution following allogeneic HSCT...
  24. ncbi GVHD pathophysiology: is acute different from chronic?
    Tomomi Toubai
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    Best Pract Res Clin Haematol 21:101-17. 2008
    ..In this chapter we briefly discuss and contrast the pathophysiologies of acute and chronic GVHD...
  25. ncbi The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells
    Heather J Symons
    Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:499-509. 2008
    ..These events provide the cellular mechanism of the "allogeneic effect" in antitumor immunity. Cy + CD8(-) DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers...
  26. ncbi [The experience in non-relative allogenic transplantation of stem hemopoietic cells in the Clinic of Bone Marrow Transplantation at I.P. Pavlov St-Petersburg Medical Academy]
    L S Zubarovskaia
    Ter Arkh 79:36-43. 2007
    ..It is necessary to create a national register of non-relative donors...
  27. ncbi Therapy of relapsed Hodgkin lymphoma
    Amanda F Cashen
    Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Blood Rev 21:233-43. 2007
    ..New salvage regimens that incorporate gemcitabine, vinorelbine, rituximab, and/or monoclonal antibodies against CD30 are being investigated...
  28. ncbi Graft-versus-host disease: a surge of developments
    Stanley R Riddell
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington, United States of America
    PLoS Med 4:e198. 2007
  29. ncbi Outcomes of transplantation in children with acute leukaemia
    Vanderson Rocha
    Bone Marrow Transplant Unit and Clinical Research Laboratory on Cell Therapy and Department of Haematology, , 75010 Paris, France
    Lancet 369:1906-8. 2007
  30. ncbi Hematopoietic cell transplantation: progress and obstacles
    M Devetten
    University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Ann Oncol 18:1450-6. 2007
    ..Long-term complications are starting to emerge, and will gain in importance in the near future...
  31. ncbi [Haploidentical 2- or 3-antigen-mismatched hematopoietic stem cell transplantation using in vivo Campath-1H]
    Yoshinobu Kanda
    Rinsho Ketsueki 47:607-17. 2006
  32. ncbi An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues
    Ronjon Chakraverty
    Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    J Exp Med 203:2021-31. 2006
    ..Our studies help to explain the paradox whereby GVH-reactive T cells can mediate graft-versus-leukemia responses without inducing GVHD in established MCs...
  33. ncbi Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction
    Daniela Montagna
    Department of Pediatrics, Laboratory of Immunology, University of Pavia, Italy
    Cancer Res 66:7310-6. 2006
    ....
  34. ncbi Vascularized lymph node transplantation induces graft-versus-host disease in chimeric hosts
    Cedric G Francois
    Plastic Surgery Research, Department of Surgery, University of Louisville, KY, USA
    Transplantation 81:1435-41. 2006
    ..This illustrates the important role of the LN microenvironment in adaptive immune responses...
  35. ncbi Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction
    Masayuki Nagasawa
    Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Am J Hematol 81:340-8. 2006
    ..These results indicate that increased release of granulysin presents alloreactivity and serum granulysin is useful as a marker of GVHD in SCT...
  36. ncbi Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  37. ncbi Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction
    Katharina Fleischhauer
    Oncoematologia Pediatrica, IRCCS Policlinico San Matteo, P le Golgi 2, 27100 Pavia, Italy
    Blood 107:2984-92. 2006
    ..82; P = .01). These data suggest that in patients with thalassemia, the incidence of graft failure after HSCT may be reduced by appropriate selection of UDs, with such selection taking into account the functional rules of immunogenetics...
  38. ncbi Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation
    James M Mathew
    Department of Surgery, University of Miami School of Medicine, Florida 33136, USA
    Transplantation 74:846-55. 2002
    ..Therefore, we questioned whether an intrinsic immunoregulatory function of (subpopulations of) DBMC might play a role in this observation...
  39. ncbi Interleukin-10 modulation of alloreactivity and graft-versus-host reactions
    Xiao-Nong Wang
    Department of Haematology, School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom
    Transplantation 74:772-8. 2002
    ..Responder cells producing high TNF-alpha following allogeneic stimulation appeared to be less sensitive to IL-10 modulation of GvHR...
  40. ncbi The H-2 major histocompatibility complex and the I immune response region: genetic variation, function, and organization
    D C Shreffler
    Adv Immunol 20:125-95. 1975
  41. ncbi Deficiency in the thymus-dependent immunity in "lethargic" mutant mice
    H C Dung
    Transplantation 23:39-43. 1977
    ..Implications of these results in understanding the immunological status of lethargic mice were considered...
  42. ncbi Non-myeloablative hematopoietic stem cell transplantation
    M Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    Transfus Clin Biol 8:231-4. 2001
    ....
  43. ncbi Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia
    G R Hill
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 104:459-67. 1999
    ..These data highlight the importance of conditioning in GVHD pathophysiology, and demonstrate that TNF-alpha is critical to GVL mediated by donor T cells, whereas IL-1 is not...
  44. ncbi A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation
    Kimmo Talvensaari
    Laboratoire d'Immunologie et d'Histocompatibilit, INSERM U.396, , , AP-HP, Paris, France
    Blood 99:1458-64. 2002
    ..These data indicate an efficient thymic regeneration pathway from CB lymphoid progenitors despite the low number of cells infused compared to bone marrow, arguing for a complete clinical immune recovery after CB transplantation...
  45. ncbi The use of H-2 mutants as models for the study of T cell activation
    I F McKenzie
    Immunol Rev 35:179-230. 1977
  46. ncbi The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment
    Iwao Okamoto
    Fujisaki Institute, Hayashibara Biochemical Laboratories, Incorporated, Japan
    Clin Immunol 103:132-44. 2002
    ..Thus, our study indicates that Kaempferol has the capacity to modulate the Th1/Th2 balance and could be useful for the treatment of cell-mediated immune diseases, such as acute GVHD...
  47. ncbi Human leucocyte antigen-Cw-specific cytotoxic T lymphocytes generated from naive cord blood used for cord blood stem cell transplantation
    Makoto Yazaki
    Department of Paediatrics, Nagoya City University Medical School, 1 Kawasumi, Mizuho cho, Nagoya 467 8601, Japan
    Br J Haematol 117:893-8. 2002
    ....
  48. ncbi Separating graft-versus-tumor from graft-versus-host reactions
    A B T Fassas
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Leuk Lymphoma 43:725-33. 2002
    ....
  49. ncbi The role of hematopoietic stem cells in the treatment of ovarian cancer
    A Perillo
    Department of Gynecology and Obstetrics, Catholic University of the Sacred Heart, Rome, Italy
    Panminerva Med 44:197-204. 2002
    ..Perspectives in the use of HSC in oncology comprise the possibility of an HSC ex vivo expansion, the use of umbilical cord blood HSC, and the development of future HSC-based gene-therapy programs...
  50. ncbi Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161
    B J Nickoloff
    Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University of Chicago, Maywood, Ill 60153, USA
    Arch Dermatol 135:546-52. 1999
    ....
  51. ncbi Suppressor function of hepatic mononuclear inflammatory cells during murine chronic graft-vs-host disease. I. Macrophage-enriched cells mediate suppression in the liver
    C D Howell
    University of Colorado School of Medicine, Denver
    Cell Immunol 132:256-68. 1991
    ..T cells contributed to the suppressor activity of both populations. However, the suppressor activity of hepatic MC was mediated largely by a macrophage-enriched population of MC while that of splenic MC was mediated largely by NS cells...
  52. ncbi A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody
    Shan He
    Institute of Health Sciences and Shanghai Institute of Immunology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China
    J Immunol 181:7581-92. 2008
    ..Thus, we have established a novel and effective approach with the potential to give rise to new clinical methods for preventing and treating GVHD after allogeneic hematopoietic stem cell transplantation...
  53. ncbi Identification of functional T cell subsets and surface antigen changes during activation as they relate to RT6
    H D Hunt
    Department of Microbiology, University of Iowa, Iowa City
    Cell Immunol 143:194-211. 1992
    ..Following a return to a nonactivated state, the T cells reexpress RT6. The loss and reexpression of RT6 may be related to activation and/or differentiation of T cells...
  54. ncbi Contribution of regulatory T cells and effector T cell deletion in tolerance induction by costimulation blockade
    Bert Verbinnen
    Division of Clinical Immunology, University Hospital, Catholic University of Leuven, Leuven, Belgium
    J Immunol 181:1034-42. 2008
    ..At later time points (>30 days after splenocyte transfer), clonal deletion of host-reactive T cells was found to be a major mechanism responsible for tolerance...
  55. ncbi The role of corticotropin-releasing hormone in blastocyst implantation and early fetal immunotolerance
    S N Kalantaridou
    Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Ioannina, Ioannina, Greece
    Horm Metab Res 39:474-7. 2007
    ..Defective uterine CRH/CRH-R1 system during early pregnancy may be implicated in the pathophysiology of recurrent miscarriage, placenta accreta, and preeclampsia...
  56. ncbi JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories Central Pharmaceutical Research Institute, Takatsuki, Japan
    Exp Hematol 36:1514-23. 2008
    ..In the present study, the role of human AILIM/ICOS in T-cell function was investigated using a fully human monoclonal antibody specific to human AILIM/ICOS (JTA-009)...
  57. ncbi Thrombotic complications after haematopoietic stem cell transplantation: early and late effects
    Dimitrios A Tsakiris
    Department of Haematology, University Hospital Basel, CH 4031 Basel, Switzerland
    Best Pract Res Clin Haematol 22:137-45. 2009
    ..This chapter will discuss the incidence, possible causative associations and treatment options of early and late thrombotic events after haematopoietic stem cell transplantation...
  58. ncbi Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity
    Marieke Griffioen
    Departments of Hematology and Immunohematology and Blood Transfusion, Leiden University Medical Center, P O Box 9600, 2300 RC, Leiden, The Netherlands
    Proc Natl Acad Sci U S A 105:3837-42. 2008
    ..We hypothesize that LB-PI4K2B-1S-specific CD4(+) T cells contributed to the antitumor response by both directly eliminating malignant cells as effector cells and stimulating CD8(+) T cell immunity as helper cells...
  59. ncbi Expression of allograft inflammatory factor-1 in inflammatory skin disorders
    Christina Orsmark
    Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
    Acta Derm Venereol 87:223-7. 2007
    ..We conclude that AIF-1 may mediate survival and pro-inflammatory properties of macrophages in skin diseases...
  60. ncbi [Immunomodulator effects of 2 antibiotics, chloramphenicol and kitasamycin, in the chicken]
    A Laval
    INRA, Ecole Nationale Veterinaire d Alfort, Maisons Alfort, France
    Ann Rech Vet 19:259-66. 1988
    ..A short stimulation of cellular response is shown with kitasamycin, which stimulates GVHR, whereas chloramphenicol has a negative effect...
  61. ncbi [Native MRT diagnosis of transplantation dysfunction--the acute graft reaction]
    J P Kuhn
    Rofo 180:669-72. 2008
  62. ncbi Functional modifications of the CD4+ and the CD8+ subset due to maternal serum
    Y E Vanderbeeken
    Service d' Immunologie, , Brussels, Belgium
    Immunopharmacol Immunotoxicol 11:397-420. 1989
    ..Appearing quite early during the gestation (at the 5-6th week), this factor was vanishing 2 weeks after the delivery...
  63. ncbi Mlsa generated suppressor cells. I. Suppression is mediated by double-negative (CD3+CD5+CD4-CD8-) alpha/beta T cell receptor-bearing cells
    M Bruley-Rosset
    Institut de la Santé et de la Recherche Medicale Unité 267, Villejuif, France
    J Immunol 145:4046-52. 1990
    ....
  64. ncbi Immune dysfunction associated with graft-vs-host reaction in mice transplanted across minor histocompatibility barriers. II. Reversible defect in T-dependent antibody responses
    S Budhecha
    Department of Biological Structure, University of Washington, Seattle 98195
    J Immunol 142:3740-5. 1989
    ....
  65. ncbi Allogeneic peripheral blood stem cell transplantation from related donors mismatched at 2 HLA loci in the host-versus-graft direction
    Toshihiko Ando
    Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan
    Tohoku J Exp Med 214:159-63. 2008
    ..Our experience suggests that PBSC transplantation with an HVG-mismatched related donor and an appropriate conditioning regimen may be a therapeutic option for patients in whom early transplantation is desirable...
  66. ncbi Motheaten, an immunodeficient mutant of the mouse. II. Depressed immune competence and elevated serum immunoglobulins
    L D Shultz
    J Immunol 116:936-43. 1976
    ..Evidence of autoimmunity was found in motheaten mice in the granular deposition of IgM and IgG in kidney glomeruli. Motheaten mice, thus, appear to have a severe immune deficiency, but the basic nature of the deficiency is not yet known...
  67. ncbi Suppression of cellular immunity by cord blood-derived unrestricted somatic stem cells is cytokine-dependent
    Meike Winter
    Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Medical Center, Dusseldorf, Germany
    J Cell Mol Med 13:2465-75. 2009
    ..Therapeutically, they may help to protect USSC and possibly their progeny from immune rejection...
  68. ncbi ABO-incompatible living-donor lobar lung transplantation
    Tsuyoshi Shoji
    Department of Thoracic Surgery, Kyoto University, 54 Shogoin Kawahara cho, Kyoto, Japan
    J Heart Lung Transplant 30:479-80. 2011
    ..To our knowledge, this case represents the first successful living-donor lobar lung transplantation from ABO-incompatible donors...
  69. ncbi Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects
    Hongfeng Guo
    Department of Hematology, Wuxi People s Hospital, Nanjing Medical University, Wuxi, China
    Onkologie 33:389-95. 2010
    ..Future manipulation to improve NK cell adoptive immunotherapy by means of increasing target recognition and reducing inhibitory signaling is being explored...
  70. ncbi Graft-versus-host disease
    S Choi
    Blood and Marrow Transplantation Program, Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0942, USA
    Panminerva Med 52:111-24. 2010
    ..In this article we review current and recent advances made in understanding of the cross-talk between these multiple cells and inflammatory molecules that have been implicated in the biology of GVHD...
  71. ncbi A pilot study of fat allograft transplantation in immunocompetent rabbits for potential neurosurgical applications
    John S Kuo
    Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, University of Toronto, Ontario, Canada
    J Neurosurg 114:441-5. 2011
    ..The authors investigated the feasibility of using fat allografts (chemically treated to reduce the host immune response) for neurosurgical applications...
  72. ncbi Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model
    Juha P Laurila
    MediCity Research Laboratory, University of Turku, Turku, Finland
    Cytotherapy 11:726-37. 2009
    ..In the present work we studied the distribution of human MSC in a rat hind limb ischemic injury model immediately after transplantation and also analyzed the recipient tissue response to transplanted cells...
  73. ncbi Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction
    Emanuela Marcenaro
    Dipartimento di Medicina Sperimentale and Centro di Eccellenza per le Ricerche Biomediche, Universita degli Studi di Genova, Genova, Italy
    Blood 114:4108-16. 2009
    ....
  74. ncbi Immunological behavior of enhanced green fluorescent protein (EGFP) as a minor histocompatibility antigen with a special reference to skin isograft and specific regulation of local graft-versus-host reaction (GvHR)
    Xuan Chao Pan
    Department of Artificial Organ and Transplantation Surgery, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyou ku, Tokyo 113 8655, Japan
    Immunol Lett 123:103-13. 2009
    ....
  75. ncbi Allogeneic memory T cell response
    Benny J Chen
    Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina, USA
    Biol Blood Marrow Transplant 14:20-2. 2008
    ..A clinical trial has been planned. Successful translation of this approach in the clinic will improve the safety, enhance the effectiveness, and broaden the scope of allogeneic hematopoietic stem cell transplantation...
  76. ncbi Minor H antigens: genes and peptides
    E Simpson
    MRC Clinical Sciences Centre, Department of Immunology, Imperial College School of Medicine, Hammersmith Hospital, London, UK
    Eur J Immunogenet 28:505-13. 2001
    ....
  77. ncbi Use of natural killer cells as immunotherapy for leukaemia
    Bartosz Grzywacz
    Division of Blood and Marrow Transplantation, University of Minnesota, MN, USA
    Best Pract Res Clin Haematol 21:467-83. 2008
    ..Future modifications to improve NK cell adoptive immunotherapy by means of increasing target recognition and reducing inhibitory signalling are being explored...
  78. ncbi Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects
    Takashi Miyake
    First Department of Pathology, Kansai Medical University, Moriguchi, Osaka, Japan
    Immunology 126:552-64. 2009
    ..Allogeneic IBM-BMT + ATT thus can induce high thymopoiesis, preserving strong GVT effects without severe GVHR...
  79. ncbi Acute graft versus host disease
    David A Jacobsohn
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology Transplant, Children s Memorial Hospital, Chicago, IL, USA
    Orphanet J Rare Dis 2:35. 2007
    ..Additional management issues are attention to wound infections in skin GVHD and fluid/nutrition management in gastrointestinal GVHD. About 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD...
  80. ncbi Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin
    Nikki B Marshall
    Department of Microbiology, Oregon State University, Corvallis, OR 97331, USA
    J Immunol 181:2382-91. 2008
    ..The generation of CD4(+) cells with regulatory function mediated through activation of the AhR by TCDD may represent a novel pathway for the induction of T-regs...
  81. ncbi Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall
    Tamara L Floyd
    Department of Surgery and Emory Transplant Center, Emory University, Atlanta, GA 30322, USA
    J Immunol 186:2033-41. 2011
    ..Thus, these data demonstrate the amount/duration of Ag exposure is a critical factor in determining Tmem's relative requirement for costimulation during the recall response after transplantation...
  82. ncbi Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity
    Chiara Borsotti
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 110:783-6. 2007
    ..These data suggest that suppressing the secretion of solTNF by donor T cells significantly decreases GVHD without impairing GVT activity...
  83. ncbi Relationship between graft-vs-host reactivity and possession of the high leukemia genotype hr-hr
    D L Gasser
    J Immunol 111:1604-6. 1973
  84. ncbi Mycophenolate mofetil in the management of alloimmune hemolytic anemia in ABO-compatible but non-identical pediatric liver transplantation
    Ruben E Quiros-Tejeira
    Department of Pediatrics, Texas Children s Hospital, Baylor College of Medicine, Houston, USA
    J Pediatr Gastroenterol Nutr 41:125-8. 2005
  85. ncbi Lichen planus-like eruption following autologous bone marrow transplantation for chronic myeloid leukaemia
    J A Pagliaro
    Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    Australas J Dermatol 42:188-91. 2001
    ..The eruption resolved with topical betamethasone valerate 0.1% cream despite the ongoing use of the immunomodulatory agent interferon-alpha2b. Such a reaction in an autologous setting has only been described once previously...
  86. ncbi Peripheral regulation of graft-versus-host alloreactivity in mixed chimeric miniature swine
    S M Kunisaki
    Transplantation Biology Research Center, Massachusetts General Hospital, MGH-East, Building 149-9019, 13th Street, Boston, MA 02129, USA
    Transplantation 72:523-6. 2001
    ....
  87. ncbi A role for cytokine measurement in therapeutic monitoring of immunosuppressive drugs following lung transplantation
    P A Corris
    Clin Exp Immunol 139:176-8. 2005
  88. ncbi The Mortimer M. Bortin Lecture: to destroy by the reaction of immunity: the search for separation of graft-versus-leukemia and graft-versus-host
    Robert L Truitt
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 10:505-23. 2004
    ....
  89. ncbi Contribution of interleukin-1 to Th1- and Th2-dependent variants of chronic graft-versus-host reaction
    V A Kozlov
    Research Institute of Clinical Immunology, Siberian Division of the Russian Academy of Medical Sciences, Novosibirsk
    Bull Exp Biol Med 132:769-71. 2001
    ..These variants of chronic graft-versus-host reaction are characterized by different changes in interleukin-1 level...
  90. ncbi [Hemolytic anemia caused by graft-versus-host reaction in ABO-nonidentical renal transplants from blood group O donors]
    R Peces
    Servicio de Nefrologia, Hospital Central de Asturias, Oviedo
    Nefrologia 21:395-401. 2001
    ..Follow-up of these patients is warranted for the early detection and optimal management may be achieved by reduction of immunosuppression and change to mycophenolate mofetil...
  91. ncbi Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy
    Els Goulmy
    Department of Immunohaematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands
    Cancer J 10:1-7. 2004
    ....
  92. ncbi Novel method for in vitro depletion of T cells by monoclonal antibody-targeted photosensitization
    T Berki
    Department of Immunology and Biotechnology, University Medical School of Pecs, Hungary
    J Immunol Methods 211:139-46. 1998
    ..This method can be useful for selective destruction of one population (target cell) in an in vitro heterogeneous cell mixture, e.g., in bone marrow transplants for T cell depletion to avoid graft vs. host reaction...
  93. ncbi [Cancer cell therapy: what future?]
    Jacques Olivier Bay
    Bull Cancer 90:675-6. 2003
  94. ncbi Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning
    Yong-Mi Kim
    Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital/Harvard Medical School, MGH-East Bldg 149-5102, 13th St, Boston, MA 02129, USA
    Blood 103:732-9. 2004
    ..Thus, DLIs can paradoxically induce marrow rejection by residual host alphabeta T cells. These results have implications for the timing of and use of subset depletion of DLIs in recipients of nonmyeloablative transplants...
  95. ncbi Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis
    Thomas L Kiss
    Bone Marrow Transplant Service, Department of Medical Oncology and Haematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Canada
    Br J Haematol 120:523-5. 2003
    ..The patient remains in complete remission 37 months following allogeneic BMT...
  96. ncbi Establishment of in vitro cellular model predicting histocompatibility in allograft
    Y Hao
    Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030
    J Tongji Med Univ 21:277-9. 2001
    ..It was suggested that the model could be used to predict correctly histocompatibility between donor and recipient...
  97. ncbi Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host
    Susanne Hummel
    Department of Tumor Progression and Tumor Defense, German Cancer Research Center, Heidelberg
    J Leukoc Biol 72:898-912. 2002
    ..Thus, concomitant depletion of host NK and donor T cells is advantageous when approaching therapeutic treatment of solid tumors by allogeneic reconstitution of the nonmyeloablatively conditioned host...
  98. ncbi Immune reconstitution in pediatric stem-cell transplantation
    J J Auletta
    Division of Pediatric Hematology Oncology, Rainbow Babies and Children s Hospital, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Front Biosci 6:G23-32. 2001
    ..Future studies addressing these findings are needed to complement novel immunotherapies emerging from the field of transplant immunology...
  99. ncbi [Proteasome inhibitors]
    J Alexandre
    Service de Medecine Interne, Unité d Oncologie Médicale, Groupe Hospitalier Cochin Saint Vincent De Paul, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Rev Med Interne 26:812-5. 2005
    ..Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis...
  100. ncbi Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation
    R L Truitt
    Department of Pediatrics and Cancer Center, Medical College of Wisconsin, Milwaukee 53226, USA
    J Immunol 163:5145-56. 1999
    ..Thus, PCT ex vivo offers a simple, rapid, and inexpensive method by which to control the fate of naive and primed T cells in vivo...
  101. ncbi Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
    Nadira Durakovic
    Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 109:4564-74. 2007
    ....

Research Grants76

  1. ORTHOTOPIC LIVER TRANSPLANTATION
    Thomas Starzl; Fiscal Year: 2001
    ..Moreover, the investigators will attempt to develop novel techniques to modify the number and character of the donor cells that ultimately reside in the recipient and promote tolerance to the allograft. ..
  2. MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB
    ROBERT TRUITT; Fiscal Year: 2001
    ..Mechanistic insights gained from the studies, together with the biological principles identified, will facilitate the translational application of MoAb to clinical BMT. ..
  3. MANIPULATION OF GVL/GVH REACTIONS IN ALLOGENEIC BMT
    ROBERT TRUITT; Fiscal Year: 1993
    ..The proposed studies will help identify strategies and reagents that merit further evaluation in clinical BMT as well as those that require modification before use...
  4. CD200 Expression on Apoptotic DCs and Immune Tolerance
    ROBERT TRUITT; Fiscal Year: 2005
    ..These studies will also provide new insight into a novel molecular pathway that is a target for enhancement of antitumor immunity and for prevention of graft rejection. ..
  5. Allospecific Immunoregulatory T Cells in BMT Recipients
    ROBERT TRUITT; Fiscal Year: 2003
    ....
  6. CLONAL GVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPY
    ROBERT TRUITT; Fiscal Year: 1990
    ..The proposed studies are a systematic approach to optimizing the GVL effect while minimizing the GVH effect of cloned CTL. In addition, they will enable us to gain significant new insights into the pathogenesis of clonal GVH reactions...
  7. HEMATOPOIETIC GROWTH FACTORS IN A CANINE STEM CELL MODEL
    Richard Nash; Fiscal Year: 2003
    ....
  8. Strategies for prenatal stem cell transplantation
    Alan W Flake; Fiscal Year: 2010
    ..The ultimate goal of these studies is to develop safe and effective strategies that can be translated to the in utero treatment of a broad range of human genetic hematologic disorders including Sickle Cell Disease and Thalassemia. ..
  9. MODULATING GVH/GVL POST-BMT USING TK EXPRESSING T CELLS
    William Drobyski; Fiscal Year: 2004
    ..The overall goal of this project is to selectively modulate T-cell function and survival in vivo in order to augment the therapeutic index of allogeneic BMT. ..
  10. Nonmyeloablative Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
    Richard Nash; Fiscal Year: 2006
    ..The unique observations in this study regarding responses and recovery of organs after inducing a sustained remission of SSc will serve to focus and direct other non-transplant research activities. ..
  11. Fetal Stromal Progenitor Cells
    Alan Flake; Fiscal Year: 2006
    ..abstract_text> ..
  12. Graft Versus Host Disease and Autoimmunity
    William Drobyski; Fiscal Year: 2007
    ....
  13. Augmentation of GVL Reactivity Without GVHD
    William Drobyski; Fiscal Year: 2007
    ..Better understanding of how to reduce this complication while at the same time preserving the beneficial effects that result from the transplant will lead to new therapies and better outcomes for patients. ..
  14. Graft Versus Host Disease and Autoimmunity
    William Drobyski; Fiscal Year: 2009
    ....
  15. Fetal Biology and Therapy Training Program
    Alan Flake; Fiscal Year: 2007
    ..Penn Graduate School and IHGT. This request is made for 2 Trainee slots in year 1, 3 Trainee slots in year 2, and 4 Trainee slots each year thereafter. ..
  16. Lung Transplantation and Immune Tolerance in Young Recipients
    Richard Nash; Fiscal Year: 2007
    ..Development of preclinical strategies for the induction of lung-specific tolerance in large animal models to prevent acute and chronic rejection will increase the probability of successful translation to human studies. ..
  17. Protection from GVHD with Gene-Modified Donor T Cells
    Richard Nash; Fiscal Year: 2007
    ....
  18. ENGRAFTING SENSITIZED HOSTS WITH NONABLATIVE REGIMENS
    Richard Nash; Fiscal Year: 2002
    ..By lessening the morbidity and mortality associated with conventional conditioning, these studies could significantly change the management of selected inherited red blood cell diseases. ..
  19. PRENATAL STRATEGIES FOR TREATMENT OF HEMOGLOBINOPATHIES
    Alan Flake; Fiscal Year: 2002
    ..abstract_text> ..
  20. GENE MODIFIED CLONED PIGS
    Thomas Starzl; Fiscal Year: 2003
    ..abstract_text> ..
  21. Regulation of Engraftment & Immunity by GD T Cells
    William Drobyski; Fiscal Year: 2005
    ....
  22. Strategies for Prenatal Stem Cell Tranplantation
    Alan Flake; Fiscal Year: 2004
    ..The studies in this proposal are designed to identify and test strategies to increase engraftment after IUHSCTx. This would allow application of this approach to a broad range of prenatally diagnosed genetic disorders. ..
  23. Augmentation of GVL Reactivity Without GVHD
    William Drobyski; Fiscal Year: 2009
    ..Better understanding of how to reduce this complication while at the same time preserving the beneficial effects that result from the transplant will lead to new therapies and better outcomes for patients. ..
  24. Strategies for prenatal stem cell transplantation
    Alan Flake; Fiscal Year: 2007
    ..The ultimate goal of these studies is to develop safe and effective strategies that can be translated to the in utero treatment of a broad range of human genetic hematologic disorders including Sickle Cell Disease and Thalassemia. ..
  25. Translational Research in Multiple Myeloma
    CAROL HUFF; Fiscal Year: 2006
    ..abstract_text> ..